CompletedNot applicableNCT00603889
Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
Studying Ankylostomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Albert B. Sabin Vaccine Institute
- Principal Investigator
- David Parenti, MD, LMFTGWUMC Medical Faculty Associates
- Intervention
- Na-ASP-2 Skin Test Reagent(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 18-45 years · All sexes
- Timeline
- 2008 – 2008
Study locations (1)
- GWUMC Clinical Trials Unit, Washington D.C., District of Columbia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00603889 on ClinicalTrials.govOther trials for Ankylostomiasis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE3NCT06736691Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth InfectionsSwiss Tropical & Public Health Institute
- RECRUITINGPHASE3NCT06282315Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessInsud Pharma
- RECRUITINGPHASE4NCT07145736Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical DiseasesKirby Institute
- RECRUITINGPHASE3NCT06128447Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)Zero Point Five Therapeutics
- RECRUITINGPHASE1NCT01940757Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm LarvaeBaylor College of Medicine